Journal of Clinical Virology, published by Elsevier, stands at the forefront of virology research, focusing on the clinical implications of viral diseases. With an impressive impact factor representative of its Q1 categorization in both Infectious Diseases and Virology, this journal is essential for researchers and healthcare professionals aiming to keep pace with evolving knowledge and treatments in virology. Since its inception in 1998, it has provided a vital platform for the dissemination of significant breakthroughs, now continuing through to 2024. The journal boasts competitive Scopus ranks, placing it in the 95th percentile for Infectious Diseases and the 91st percentile for Virology. Scholars can benefit from its selective Open Access options, promoting widespread access to cutting-edge research. With an ever-increasing demand for innovative solutions to viral infections, Journal of Clinical Virology remains dedicated to fostering advancements in the field, making it a key resource for anyone invested in virology and infectious disease management.

Eurosurveillance is a prestigious journal dedicated to the field of epidemiology, public health, and infectious diseases, published by the European Centre for Disease Prevention and Control since 1996. With an impressive Q1 ranking across various categories, including Epidemiology and Public Health, it consistently stands at the forefront of research dissemination, making it an invaluable resource for researchers, professionals, and students alike. The journal boasts an outstanding reputation, as evidenced by its Scopus rankings, where it ranks in the top 1% to 3% in multiple relevant categories. As an Open Access publication, Eurosurveillance ensures that vital findings are freely accessible to a global audience, fostering collaboration and innovation in the fight against infectious diseases. With a dedicated reach from 2001 to 2024, the journal addresses contemporary challenges in public health and virology, reinforcing its significance in shaping policies and research initiatives across the world.

SEMINARS IN IMMUNOLOGY, published by Academic Press Ltd - Elsevier Science Ltd, stands as a leading journal in the field of immunology and allergy, with an impressive impact factor that reflects its significant contribution to advancing research and discourse within these vital areas of medical science. Established in 1989, this esteemed journal has garnered a reputation for disseminating high-quality, peer-reviewed articles that span a broad spectrum of immunological topics, making it an essential resource for researchers, healthcare professionals, and students alike. Currently ranked Q1 in both Immunology and Allergy categories, SEMINARS IN IMMUNOLOGY ranks 39th among 233 journals in Immunology and Allergy and 43rd among 236 in Immunology and Microbiology according to Scopus, placing it in the 83rd and 81st percentiles respectively. This underscores its pivotal role in shaping the future of immunological research and clinical practices. While the journal operates under a subscription model with no open access option, it remains committed to providing comprehensive insights and fostering scholarly collaboration within the global immunology community.

npj Vaccines, published by NATURE PORTFOLIO, is an esteemed Open Access journal that has been at the forefront of vaccination research since its inception in 2016. With an impressive impact factor and ranking in the top quartile (Q1) across several categories including Immunology, Infectious Diseases, and Pharmacology, this journal provides a crucial platform for the dissemination of high-quality research and innovative findings in the field of vaccine development. Based in the United Kingdom, and with its broad scope encompassing both fundamental and translational studies, npj Vaccines facilitates significant discourse among researchers, professionals, and students dedicated to immunization strategies and public health. The journal's commitment to Open Access ensures that vital knowledge is shared widely, promoting collaboration and advancement in vaccine science on a global scale. Scholars are encouraged to contribute to this essential field, as their findings may significantly impact the future of disease prevention and control.

Vaccine: X, published by Elsevier, is a premier open access journal dedicated to advancing research in the interdisciplinary fields of immunology and microbiology, infectious diseases, molecular medicine, and public health. With an ISSN of 2590-1362 and operating since 2019, the journal has rapidly established an influential role, achieving Q2 rankings in major categories such as Immunology and Microbiology, Infectious Diseases, and Public Health for 2023. Its commitment to disseminating cutting-edge research is evident from its broad scope, focusing on innovative vaccines and therapies that are critical for global health. Researchers and professionals will find value in the accessible nature of the journal, which has been recognized for its contributions to veterinary medicine as well, with a Q1 ranking in the miscellaneous veterinary category. The journal proudly showcases high-quality, peer-reviewed articles and welcomes submissions that push the boundaries of current knowledge, making it an essential resource for anyone involved in vaccine research and development.

AIMS Allergy and Immunology is a prestigious open access journal dedicated to advancing knowledge in the fields of allergy and immunology. Published by the American Institute of Mathematical Sciences (AIMS), this journal provides a vibrant platform for researchers, practitioners, and scholars to share groundbreaking findings and insights. Recognized for its commitment to disseminating high-quality research since its inception in 2017, AIMS Allergy and Immunology contributes significantly to the understanding of complex immunological mechanisms and allergic responses, thus playing a pivotal role in enhancing clinical practices and therapeutic strategies. With its ISSN 2575-615X, the journal aims to facilitate a robust exchange of ideas and promote collaboration within the scientific community. Researchers and practitioners are encouraged to access the latest studies and reviews, which are all freely available online, ensuring that vital information reaches a global audience without barriers. Together, we can tackle the challenges posed by allergies and immune disorders through rigorous scientific inquiry and innovation.

EPIDEMIOLOGIE MIKROBIOLOGIE IMUNOLOGIE is a prominent scholarly journal published by CESKA LEKARSKA SPOLECNOST J EV PURKYNE in the Czech Republic. With an ISSN of 1210-7913, this journal has been at the forefront of research since its inception in 1994, showcasing a rich repository of studies bridging the domains of epidemiology, microbiology, immunology, and infectious diseases, and reflecting advancements over three decades. Although it currently falls within the Q4 category in multiple fields including Epidemiology and Microbiology, the journal serves an essential role in disseminating knowledge and fostering discussions around public health challenges. The contributions made through its pages are vital for researchers, healthcare professionals, and students aiming to enhance their understanding of complex biomedical issues. While it does not offer open access, the journal remains a critical resource in its niches, inviting readers to engage with the latest findings and methodologies reshaping the landscape of health science.

INFECTION GENETICS AND EVOLUTION is a premier scholarly journal published by Elsevier, focusing on the dynamic field of infection genetics and evolutionary biology. Since its inception in 2001, this journal has emerged as a critical platform for the dissemination of cutting-edge research, bridging the gap between molecular genetics, evolutionary theory, and infectious disease study. With an influence profound enough to secure its status in the Q1 category for Ecology, Evolution, Behavior and Systematics and impressive Q2 rankings in Genetics, Infectious Diseases, and Microbiology, the journal offers researchers unparalleled insights that advance the understanding of pathogen evolution and host interactions. Despite the lack of Open Access, the research published in this journal significantly contributes to the academic discourse and informs public health approaches. By publishing high-quality studies and reviews through 2024, INFECTION GENETICS AND EVOLUTION remains indispensable for academics, professionals, and students seeking to explore the intricate mechanisms of infection and adaptation in various organisms.

Science Immunology, published by the American Association for the Advancement of Science, is a leading journal in the field of immunology, recognized for its significant impact and rigor in advancing our understanding of immune responses and complex diseases. With an impressive impact factor that places it in the Q1 category of both immunology and allergy, as well as miscellaneous medicine, this journal is ranked #7 and #8 in their respective Scopus categories, reflecting its high-quality research output. Since its inception in 2016, Science Immunology has been at the forefront of interdisciplinary immunological research, fostering crucial insights that link immunology with pressing health challenges. The journal is committed to providing open access to its content, ensuring that groundbreaking findings are accessible to a global audience of researchers, professionals, and students. Its anthology not only addresses fundamental immunological mechanisms but also enhances the dialogue on translational applications and therapeutic interventions, solidifying its position as an essential resource within the scientific community.

Tropical Diseases Travel Medicine and Vaccines, published by SPRINGERNATURE, stands at the forefront of research in the fields of infectious diseases and public health, with an impressive impact factor that signifies its relevance and influence. Since its inception in 2015, this peer-reviewed journal has maintained an open access policy, ensuring that cutting-edge research on tropical diseases and travel medicine is readily available to researchers, professionals, and students worldwide. The journal currently ranks in the Q2 Quartile for both Infectious Diseases and Public Health, Environmental and Occupational Health, reflecting its substantial contribution to these critical areas of study. With a strong Scopus rank of #176 in Public Health and #138 in Infectious Diseases, it serves as a vital platform for innovative studies that advance understanding and response strategies related to tropical diseases. For its vast audience, Tropical Diseases Travel Medicine and Vaccines not only acts as a bridge connecting researchers with practical applications but also nurtures academic discourse essential for future advancements in global health.